Informed consent was obtained from all patients for being included in the study. 2.2 Medications Seven patients enrolled in this study were treated by twice-daily injection of insulin glargine or detemir. According to the degludec dosage guide in Japan (Novo Nordisk Pharma, Ltd., Tokyo, Japan) , patients were started
with twice-daily injection of insulin glargine or detemir and then switched to once-daily injection of degludec Omipalisib at an initial dose that was 80–90 % of the respective dose of glargine or detemir . Degludec was administered at a time of day suitable for their lifestyle. During the study period, the basal insulin doses were adjusted by the attending physician in a titration protocol as shown in Table 1. Compound C Table 1 Fasting plasma ARN-509 nmr glucose levels and basal insulin doses during the 24-week study period Fasting plasma glucose level
(mg/dL) Dose adjustment of degludec ≤80 Decreased 10–20 %/day 81–150 No adjustment 151–200 Increased 10 %/day (or 1–2 U/day) ≥201 Increased 10–20 %/day (or 2–3 U/day) U units For pre-prandial insulin supplementation, insulin aspart or lispro was administered at a dose set by the carbohydrate counting method, which remained unchanged throughout the study period. 2.3 Meals During the study period, all patients were given a test diet (1,500–1,600 kcal/day; 55–60 % carbohydrates, 15–20 % protein, 20–25 % fat) when CGM evaluation was performed before and 3 days and 24 weeks after switching to insulin degludec (Fig. 1). Fig. 1 Study design. CGM continuous glucose monitoring, HbA 1c glycated hemoglobin, W week 2.4 Continuous Glucose Monitoring (CGM) The study
design is shown Chlormezanone in Fig. 1. CGM was performed using an iPro™ 2 (Medtronic Minimed, Northridge, CA, USA) monitor before, 3 days after, and about 24 weeks after switching to insulin degludec. Evaluation of the CGM data was started while the patients were using glargine or detemir and was continued until the third day after switching to insulin degludec, when its blood concentration reached steady state . The CGM data obtained before switching and at the third day after switching were then compared. Furthermore, evaluation of the glucose profile at 24 weeks was conducted on the second day. 2.5 Glycated Hemoglobin HbA1c was measured just before switching and when CGM evaluation was performed at about 24 weeks after switching to insulin degludec. 2.6 Statistical Analysis Variables are expressed as the mean ± SD. The Wilcoxon signed-ranks test was used to compare daily glucose fluctuations and the change of insulin dose before and 3 days after switching to degludec. This test was also used to compare daily glucose fluctuations and the change of HbA1c and insulin doses until about 24 weeks after switching to degludec. StatView version 5.